Trial reportPsychology research and behavior management2026
Enhancing Methylphenidate's Neurocognitive Effects in Pediatric ADHD with Adaptive Digital Therapy: A Randomized Controlled Trial.
Trial report in Psychology research and behavior management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Digital therapeutics have emerged as promising adjuncts to pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), yet evidence from rigorously designed trials remains limited. This study aimed to evaluate the additive neurocognitive benefits of an adaptive digital therapy (Focus Pro) when combined with methylphenidate (MPH) in children with ADHD. Methods: In the present single-center, double-blind, randomized controlled trial, 85 children (6-12 years old) diagnosed with ADHD were assigned to receive MPH plus Focus Pro (n=44) or MPH alone (n=41) over an eight-week treatment period, with follow-up assessments at week 12. The digital therapy consisted of daily 25-minute sessions that targeted attention and executive functioning. The primary outcomes included objective neurocognitive measures assessed by the Test of Variables of Attention (TOVA), alongside secondary outcomes based on parent-reported scales (Swanson, Nolan, and Pelham Rating Scale, Fourth Edition [SNAP-IV], Weiss Functional Impairment Rating Scale, and Clinical Global Impressions-Severity). The analysis employed mixed repeated-measures ANOVA under an intention-to-treat framework. Results: Although both groups exhibited comparable improvements on subjective measures, the combination group demonstrated significantly greater gains in objective neurocognitive performance, particularly on TOVA attention comparison scores, at week eight ( Conclusion: The integration of adaptive digital therapy with MPH can significantly enhance neurocognitive outcomes in pediatric ADHD, particularly in sustained attention and inhibitory control. These findings highlight the clinical potential of personalized digital tools, and underscore the importance of incorporating objective assessments when evaluating digital interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.